In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer.
Dr Shiksha Gallow, Medical Director of Biodata and Head Researcher at Cannabis Oil Research, provides evidence-based research on cannabinoids for treating MS and Prostate Cancer.
The work of the Centers for Disease Control and Prevention, within the U.S. Department of Health & Human Services is examined here, with a special focus on traumatic brain injury.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, provides a cancer focus, in particular, she details breakthrough technologies that allow leveraging biomarkers for oncology.
Ahead of World Pancreatic Cancer Day, Professor Matthias Löhr, a member of the UEG Public Affairs Committee, explains why we must increase pancreatic cancer awareness.
Swarms of nanoparticles which are 15,000 times smaller than a pinhead may be able to deliver vital drugs to the brain, offering new hope to stroke patients.
More than 130 people joined The Oral Health Foundation yesterday, at the Houses of Parliament, as the charity announced this year's Mouth Cancer Action Month.
Young people with cancer are potentially being robbed of the ability to have children as important information around fertility is not being communicated at the earliest opportunity says the cancer charity, Teenage Cancer Trust.
In this exclusive interview with Prof Olufunmilayo Lesi, Regional Medical Officer for Viral Hepatitis from the World Health Organization (WHO) Office for the Africa Region, discusses tackling viral hepatitis in Africa.
After a career spanning more than 20 years, a Swansea University Professor’s passion for research is as ‘strong as ever’, as he marks a very notable achievement – the release of his 100th cancer research paper.
Using cross-disciplinary technology, Dr Kunio Matsumoto, PhD, Professor at Kanazawa University in Japan is extending research on growth factor toward synthetic biologics for regeneration-based medicine and cancer theranostics.
Regina Fluhrer from the University of Augsburg and Bernd Schröder from the TU in Dresden discuss the potential of intramembrane proteases as targets for cancer therapies.
Redefining efficiency based on what matters to cancer patients is placed under the spotlight here by All.Can, including identifying opportunities for change.
